Anika Therapeutics, Inc. (ANIK)

Revenue by Segment

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Medical Products	112.82M	119.91M	120.79M	113.83M	147.79M
Medical Products Growth	-5.91%	-0.73%	6.12%	-22.98%	13.29%
Total	112.82M	119.91M	120.79M	113.83M	147.79M
Total Growth	-5.91%	-0.73%	6.12%	-22.98%	13.29%

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
United States	70.06M	82.45M	86.91M	83.75M	113.83M
United States Growth	-15.03%	-5.14%	3.78%	-26.43%	10.32%
Europe	22.21M	19.40M	17.31M	17.23M	19.58M
Europe Growth	14.49%	12.07%	0.50%	-12.02%	38.09%
Other	20.55M	18.06M	16.57M	12.85M	14.38M
Other Growth	13.78%	8.99%	28.89%	-10.62%	9.81%
Total	112.82M	119.91M	120.79M	113.83M	147.79M
Total Growth	-5.91%	-0.73%	6.12%	-22.98%	13.29%

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jun 22, 2026

Data Sources Report a data error